Advances in experimental medicine and biology, v. 313.
Proceedings of an international symposium ... held September 1-6, 1991, in Uppsala, Sweden--Title page verso.
Historical Aspects --;Heparin-An Introduction --;Structural Properties of Heparin and Heparan Sulphate --;Chemical Synthesis and Hemisynthesis in the Field of Glycosaminoglycans --;Structural Analysis of Periodate-Oxidized Heparin --;New Methodologies in Heparin Structure Analysis and the Generation of LMW Heparins --;Heparan Sulphate Proteoglycans: Molecular Organisation of Membrane-Associated Species and an Approach to Polysaccharide Sequence Analysis --;Heparin and Heparan Sulphate Proteoglycanscellular Aspects --;Regulation of the Gene that Encodes the Peptide Core of Heparin Proteoglycan and Other Proteoglycans that are Stored in the Secretory Granules of Hematopoietic Cells --;Structural and Functional Diversity of the Heparan Sulphate Proteoglycans --;Syndecan-ACell Surface Proteoglycan that Selectively Binds Extracellular Effector Molecules --;Heparan Sulphate Proteoglycans and Signalling in Cell Adhesion --;Heparin and Heparan Sulphate Proteoglycansinteractions and Metabolism --;Animal Cell Mutants Defective in Heparan Sulphate Polymerization --;Two Enzymes in One: N-Deacetyation and N-Sulpfation in Heparin Biosynthesis are Catalyzed by the Same Protein --;Metabolism of Plasma Membrane-Associated Heparan Sulphate Proteoglycans --;Lysosomal Degradation of Heparin and Heparan Sulphate --;Heparin Binding Properties of the Carboxyl Terminal Domain of [A103,106,108] Antristasin 93-119 --;Heparin Protein Interactions --;Anticoagulant Proteins --;Role of Protein Conformational Changes, Surface Approximation, and Protein Cofactors in Heparin-Accelerated Antithrombin-Proeinase Reations --;The Interaction of Glycosaminoglycans with Heparin Cofactor II: Structure and Activity of a High-Affinity Dermatan Sulphate Hexasaccharide --;Thrombomodulin: An Anticoagulant Cell Surface Proteoglycan With Physiologically Relevant Glycosaminoglycan Moiety --;The Interaction Between LACI and Heparin --;Tissue Pathway Inhibitor and Heparin --;Antithrombotic Mechanisms --;LMW Heparin: Relationship Between Antithrombotic and Anticoagulant Effects --;The Mode of Action of Heparins In Vitro and In Vivo --;Prophylactically Effective Doses of Enoxaparin and Heparin Inhibit Prothrombin Activation --;Clinical Use --;Pharmacokinetics of Heparin and of Dematan Sulphate: Clinical Implications --;Heparin in the Prevention and Treatment of Arterial Thromboembolism --;Glycosaminoglycans in the Prophylaxis Against Venous Thromboembolism --;Treatment of Deep Vein Thrombosis (DVT) with Low Molecular Weight Heparin (LMWH) --;Relationship Between Dose, Anticoagulant Effect and the Clinical Efficacy and Safety of Heparin --;New Perspectives --;Regulation of Protease Nexin-1 Activity by Heparin and Heparan Sulphate --;New Approaches for Defining Sequence Specific Synthesis of Heparan Sulphate Chains --;Modulation of Neovascularization and Metastasis Species of Heparin --;Anti-inflammatory Effects of Heparin and its Derivatives: Inhibition of Complement and of Lymphocyte Migration --;Heparan Sulphate Glycosaminoglycans as Primary Cell Surface Receptors for Herkpes Simplex Virus --;Control of Angiogenesis by Heparin and Other Sulphated Polysaccharides.
This volume is a record of a meeting entitled "Heparin and Related Polysaccharides" that was held at the Biomedical Center, Uppsala, Sweden between 1-6 September 1991. Altogether, 230 participants from 18 countries attended the meeting, and most were present to be included in a photograph, which is to be found at the end of this volume.
Glycosaminoglycans.
Heparin -- Congresses.
Mucopolysaccharides -- Congresses.
QP702
.
H4
E358
9999
edited by David A. Lane, Ingemar Björk, and Ulf Lindahl.